John Sundy
Director/Board Member presso SANOFI
Profilo
John Sundy is currently an Independent Director at Sanofi and a Director at Neutrolis, Inc. Previously, he held the position of Senior Vice President at Gilead Sciences, Inc. from 2014 to 2020.
He also served as an Associate Professor at Duke University and Duke-NUS Graduate Medical School Singapore from 2006 to 2014.
Additionally, he was the Chief Medical Officer at Pandion Therapeutics, Inc. Dr. Sundy completed his undergraduate degree at Bucknell University and obtained doctorate degrees from Drexel University College of Medicine and Hahnemann University.
Posizioni attive di John Sundy
Società | Posizione | Inizio |
---|---|---|
SANOFI | Director/Board Member | 30/04/2024 |
Neutrolis, Inc.
Neutrolis, Inc. Pharmaceuticals: MajorHealth Technology Neutrolis, Inc. is a biotechnology company located in North Cambridge, MA. The company develops first-in-class therapies that target neutrophils and their pathogenic products, including nets. Neutrolis proprietary platform, Chromatinase™, is based on the naturally occurring enzymes that break down the extracellular chromatin that form nets. The company's lead product, NTR-441, is a patented, first-in-class, engineered DNASE1L3 analog with potential application in COVID-19, ARDS, lupus, rheumatoid arthritis, systemic sclerosis, and other net-mediated diseases. Neutrolis has received two competitive LabCentral Golden Ticket awards from Pfizer and Bristol-Myers Squibb. The company was founded by Abdul Hakkim and Toby Fox. Toby Fox has been the CEO since incorporation. | Director/Board Member | - |
Precedenti posizioni note di John Sundy
Società | Posizione | Fine |
---|---|---|
GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/04/2020 |
Duke University
Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | Corporate Officer/Principal | 01/01/2014 |
Duke-NUS Graduate Medical School Singapore | Corporate Officer/Principal | 01/01/2014 |
PANDION THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Formazione di John Sundy
Bucknell University | Undergraduate Degree |
Hahnemann University | Doctorate Degree |
Drexel University College of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
SANOFI | Health Technology |
Aziende private | 2 |
---|---|
Pandion Therapeutics, Inc.
Pandion Therapeutics, Inc. BiotechnologyHealth Technology Pandion Therapeutics, Inc. is a clinical stage biopharmaceutical company. It develops Therapeutic Autoimmune reguLatOry proteiN (TALON) drug design and discovery platform, which employ a modular approach to create a pipeline of product candidates using immunomodulatory effector modules that act at known control nodes within the immune network. The company was founded by Dr. Joanne Viney on September 19, 2016 and is headquartered in Watertown, MA. | Health Technology |
Neutrolis, Inc.
Neutrolis, Inc. Pharmaceuticals: MajorHealth Technology Neutrolis, Inc. is a biotechnology company located in North Cambridge, MA. The company develops first-in-class therapies that target neutrophils and their pathogenic products, including nets. Neutrolis proprietary platform, Chromatinase™, is based on the naturally occurring enzymes that break down the extracellular chromatin that form nets. The company's lead product, NTR-441, is a patented, first-in-class, engineered DNASE1L3 analog with potential application in COVID-19, ARDS, lupus, rheumatoid arthritis, systemic sclerosis, and other net-mediated diseases. Neutrolis has received two competitive LabCentral Golden Ticket awards from Pfizer and Bristol-Myers Squibb. The company was founded by Abdul Hakkim and Toby Fox. Toby Fox has been the CEO since incorporation. | Health Technology |
- Borsa valori
- Insiders
- John Sundy